Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPN-102
- Development stage
- Preclinical
- Lead developer
- Hepanova
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
HPN-102 is a GalNAc-conjugated small interfering RNA (siRNA) therapeutic being developed by Hepanova for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with stage F2 to F3 fibrosis. The drug utilizes a N-acetylgalactosamine (GalNAc) conjugation strategy to facilitate targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). Once inside the liver cells, the siRNA is designed to silence a specific hepatic mRNA target involved in the pathogenesis of MASH and liver fibrosis through the RNA interference (RNAi) pathway. While the specific molecular target has not been publicly disclosed by the developer, the modality is intended to reduce liver inflammation and fibrogenesis.
- Other names
- HPN-102-Hepanova-siRNAHPN102-Hepanova-siRNAHPN 102-Hepanova-siRNA
02
Targets
SREBP-1 / SREBF1 (SREBP-1)
Beyond the preview
Go deeper on HPN-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPN-102.